Ianiro Gianluca, Bibbò Stefano, Gasbarrini Antonio, Cammarota Giovanni
Institute of Internal Medicine Catholic University of Rome, Italy, Largo A. Gemelli, 8 - 00168 - Roma, Italia.
Curr Drug Targets. 2014;15(8):762-70. doi: 10.2174/1389450115666140606111402.
Human beings and gut microbiota are in a symbiotic relationship, and the hypothesis of a "super organism" composed of the human organism and microbes has been recently proposed. The gut microbiota fulfills important metabolic and immunological tasks, and the impairment of its composition might alter homeostasis and lead to the development of microbiota-related diseases. The most common illnesses associated with alterations of the gut microbiota include inflammatory bowel disease, gastroenteric infections, irritable bowel syndrome and other gastrointestinal functional diseases, colorectal cancer, metabolic syndrome and obesity, liver diseases, allergic diseases, and neurological diseases such as autism. In theory, every disease associated with the impairment of intestinal microflora might benefit from the therapeutic modulation of the gut microbiota. A number of attempts to manipulate the microbiota have not produced identical results for every disease. Although antibiotics and probiotics have been available for a long time, the so-called fecal microbiota transplantation, which is a very old remedy, was only recently re-evaluated as a promising therapeutic approach for microbiota impairment. A comprehensive understanding of the gut microbiota composition, in states of both health and various diseases, is needed for the development of future approaches for microbiota modulation and for developing targeted therapies. In this review, we describe the role of the microbiota in several diseases and the related treatment options that are currently available.
人类与肠道微生物群处于共生关系,最近有人提出了由人体有机体和微生物组成“超级生物体”的假说。肠道微生物群执行重要的代谢和免疫任务,其组成的改变可能会破坏体内平衡并导致微生物群相关疾病的发生。与肠道微生物群改变相关的最常见疾病包括炎症性肠病、胃肠道感染、肠易激综合征和其他胃肠功能性疾病、结直肠癌、代谢综合征和肥胖症、肝脏疾病、过敏性疾病以及诸如自闭症等神经疾病。理论上,每一种与肠道微生物群受损相关的疾病都可能从肠道微生物群的治疗性调节中获益。一些操纵微生物群的尝试对每种疾病并未产生相同的结果。尽管抗生素和益生菌已经存在很长时间了,但所谓的粪便微生物群移植,这是一种非常古老的疗法,直到最近才被重新评估为一种治疗微生物群受损的有前景的治疗方法。为了开发未来调节微生物群的方法和开发靶向疗法,需要全面了解健康状态和各种疾病状态下的肠道微生物群组成。在这篇综述中,我们描述了微生物群在几种疾病中的作用以及目前可用的相关治疗选择。